PTC Therapeutics today announced new data suggesting that the quantification of cough frequency may offer a clinically meaningful
“The ability to quantify cough represents a significant step forward in our understanding of one of the most prominent symptoms of CF,” said Preston W. Campbell, III, M.D., executive vice president for medical affairs of the Cystic Fibrosis Foundation. “A significant reduction in cough frequency would be of real value to patients.”
The study was designed to assess cough frequency as a measure of clinical benefit. Quantitative measurement was achieved using a new technology, the VivoMetrics® LifeShirt®, which integrates cough signals from chest wall motion transducers and a throat microphone and stores the data for computer analysis.